You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
GenapSys will offer the Twist Bioscience products to customers of its recently launched low-cost, portable DNA sequencing system.
Among the firm's distributors in the Asia-Pacific region are Research Instruments of Singapore, Biomedical Systems of Korea, and Gene Company of Hong Kong.
On the second day of the conference, updates came not just from the publicly traded industry giants but also privately held firms of interest, such as Caris and GenapSys.
Researchers at the Jackson Laboratory have tested an early version of the GenapSys sequencer and found it to have a very low mismatch error rate.
The Redwood, California-based company plans to use the funding to drive the commercial launch of its semiconductor chip-based sequencing-by-synthesis instrument.
Genapsys plans to launch its electronic sensor-based sequencing system in the second half of this year.
Genapsys plans to launch the portable instrument in the second half of this year, and has signed on several early-access customers.
Meridian CEO Jack Kenny said the firm needs to develop a new MDx platform, while Genapsys resurfaced with an update on its portable sequencing platform.
Sigma-Aldrich has been developing reagents for the Genius platform for about a year.
This article was originally published February 17.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.